07:00 , May 19, 2016 |  BC Innovations  |  Distillery Therapeutics

Therapeutics: Catechol-O-methyl-transferase (COMT)

Neurology INDICATION: Parkinson's disease (PD) In vitro studies identified a thiazolidinedione-based COMT inhibitor that could help treat PD. Directed structure-based drug design and in vitro testing identified a thiazolidinedione analog that inhibited the activity of...
07:00 , Oct 29, 2012 |  BC Week In Review  |  Company News

caprotec management update

caprotec bioanalytics GmbH , Berlin, Germany   Business: Proteomics, Supply/Service   Hired: Jonathan Turner as CEO and managing director, formerly SVP at XL Techgroup Inc.; he replaces Hubert Koester, who becomes acting CSO and chairman...
07:00 , May 16, 2011 |  BC Week In Review  |  Financial News

caprotec financial update

Caprotec raised €1 million ($1.4 million) in the second close of a series B round, bringing the total raised in the round to €5 million ($6.4 million). The company raised €4 million ($4.9 million) in...
07:00 , Oct 11, 2010 |  BC Week In Review  |  Company News

caprotec sales and marketing update

caprotec bioanalytics GmbH , Berlin, Germany   Business: Proteomics   caprotec bioanalytics launched three new caproKits to investigate small molecule-protein interactions and discover, identify and characterize proteins: Dasatinib caproKit, C2 cAMP caproKit and Biotin Capping...
07:00 , Oct 11, 2010 |  BC Week In Review  |  Company News

caprotec management update

caprotec bioanalytics GmbH , Berlin, Germany   Business: Proteomics, Supply/Service   Hired: Rainer Metternich as CBO, COO and a director, formerly VP and basic research site head at Merck & Co. Inc.  ...
07:00 , May 24, 2010 |  BC Week In Review  |  Financial News

caprotec completes venture financing

caprotec bioanalytics GmbH , Berlin, Germany   Business: Proteomics, Supply/Service   Date completed: 5/13/10   Type: Venture financing   Raised: €4 million ($4.9 million)   Investors: Creathor Venture; IBB Beteiligungsgesellschaft; ERP Startfonds; private investors  ...
08:00 , Feb 1, 2010 |  BC Week In Review  |  Company News

caprotec sales and marketing update

caprotec launched its Marimastat, SAHA and GDP caproKits worldwide to discover, identify and characterize proteins as metallo-proteases, histone deacetylases (HDACs) or GDP/GTP binding proteins, respectively. The kits are available for research use. caprotec bioanalytics GmbH...
07:00 , Apr 13, 2009 |  BioCentury  |  Finance

Ebb & Flow

In its $31 million financing this month, Savient Pharmaceuticals Inc. (NASDAQ:SVNT) employed a novel warrant structure that allowed it to finance ahead of a significant binary event without having to provide an upfront premium based...
08:00 , Jan 26, 2009 |  BC Week In Review  |  Company News

caprotec sales and marketing update

caprotec launched its SAH and cAMP caproKits to discover, identify and characterize proteins that interact with S-adenosyl-L-homocysteine (SAH), S-adenosyl-L-methionine (SAM) and cyclic adenosine monophosphate (cAMP), respectively. caprotec bioanalytics GmbH , Berlin, Germany   Business: Proteomics...
07:00 , Jun 2, 2008 |  BC Week In Review  |  Company News

caprotec, Merck KGaA deal

caprotec will use its Capture Compound Mass Spectrometry (CCMS) technology to identify protein-drug interactions for an undisclosed research project conducted by Merck KGaA’s Merck Serono S.A. subsidiary. Caprotec will receive undisclosed research funding and is...